To include your compound in the COVID-19 Resource Center, submit it here.

Exelixis, Bristol-Myers deal

Exelixis said Bristol-Myers will return all rights under a 2008 deal to XL281, effective Oct. 8. According to Exelixis,

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE